mitochondrial DNA

Overview

Mitochondrial DNA (mtDNA) is the small, circular genome located within mitochondria, the organelles responsible for oxidative phosphorylation and cellular energy production. In humans, mtDNA encodes a limited set of genes essential for respiratory chain function, while the majority of mitochondrial proteins are encoded by nuclear DNA and imported into the organelle. Because mtDNA is present in multiple copies per cell and is closely tied to mitochondrial metabolism, its integrity, copy number, and inheritance pattern are biologically important for normal cellular function.

Clinically, mtDNA is relevant to a wide range of diseases because mutations, depletion, damage, or abnormal release of mtDNA can impair energy metabolism and also act as a danger signal. When mtDNA escapes from mitochondria into the cytoplasm or extracellular space, it can activate innate immune pathways such as cGAS-STING and, in some settings, the NLRP3 inflammasome, contributing to inflammation. mtDNA variation is also widely used in population genetics and haplogroup analysis, and it remains a major target in mitochondrial disease research, neurodegeneration, cardiometabolic disease, cancer biology, and diagnostic assay development.

Focus of Latest Publications

Recent investigations have established mitochondrial DNA (mtDNA) as a critical danger-associated molecular pattern that triggers innate immune responses across diverse pathological contexts. Multiple studies demonstrate that mtDNA release from mitochondria activates the cGAS-STING signaling pathway, a central node in innate immunity. Research has characterized distinct mechanisms enabling this release: oxidative stress promotes voltage-dependent anion channel 1 (VDAC1)-mediated leakage in fibroblasts; radiation and genotoxic stress induce senescence-associated mtDNA discharge; and cuproptosis-driven mitochondrial collapse causes mtDNA efflux. Once released, cytosolic mtDNA potently activates cGAS-STING and related inflammasome pathways, driving proinflammatory cytokine production and immune cell activation.

Recognizing mtDNA release as a pathological driver, several therapeutic strategies focus on suppressing its leakage to attenuate disease progression. In radiation-induced pulmonary fibrosis, emodin preserved mitochondrial integrity and prevented mtDNA cytoplasmic accumulation, thereby blocking senescence-associated inflammation and fibrosis. Similarly, metformin inhibited mtDNA release in Huntington's disease, reducing microglial activation and neuroinflammation in affected brain regions. In vitiligo, pharmacological inhibition of VDAC1 oligomerization prevented mtDNA leakage from dermal fibroblasts, attenuating the cGAS-STING-driven inflammatory cascade that drives melanocyte destruction.

Conversely, recent cancer immunotherapy approaches deliberately harness mtDNA release as an immune-activating mechanism. Copper nanoassemblies engineered with tumor-targeting peptides trigger cuproptosis-mediated mitochondrial collapse and mtDNA release in cervical cancer cells, activating cGAS-STING-interferon regulatory factor 3 signaling and reshaping the antitumor immune microenvironment. Similarly, programmable DNAzyme nanocatalysts induce sustained reactive oxygen species accumulation and mitochondrial dysfunction, leading to mtDNA cytosolic accumulation and cGAS-STING activation; this transient immune sensitization window enhances dendritic cell maturation and cytotoxic T cell infiltration when combined with checkpoint inhibitors.

Beyond direct mitochondrial dynamics, mtDNA serves as a cargo molecule in extracellular vesicles, mediating intercellular communication with systemic consequences. Lipid-overloaded Sertoli cells release extracellular vesicles enriched in mtDNA, which, when taken up by spermatogonia, induce oxidative stress and reprogramming of germ cell metabolism. Paternally inherited mtDNA-containing vesicles subsequently predispose offspring to developmental retardation and heightened susceptibility to metabolic disease, including hepatic lipid accumulation, highlighting mtDNA's dual role as both a local inflammatory trigger and a systemically transmitted signal governing metabolic and immune homeostasis.

Key Publications

• NEWJun Biomedical publication details. (PubMed Database, 2026, PMID 42405973)
• May Paternal Sertoli cell-derived extracellular vesicles transfer mtDNA and microRNA cargo to trigger germ cell oxidative stress and induce metabolic risks in offspring. (Cell communication and signaling : CCS, 2026, PMID 42098702): "Omics sequencing revealed that lipid-overloaded Sertoli cells secreted mitochondrial-rich EVs containing mitochondrial DNA (mtDNA) and miR-6240, induced oxidative stress and repressed Creb1/Crem in recipient germ cells."
• Jun GE11/RGD Dual-Ligand Copper Nanoassemblies Synchronize Cuproptosis and Photothermal Therapy for Targeted Cervical Cancer Ablation. (Molecular pharmaceutics, 2026, PMID 42044237): "The leaked mitochondrial DNA (mtDNA) further activates the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING)-interferon regulatory factor 3 (IRF3) pathway, reshaping the antitumor immune microenvironment."
• Apr Programmable DNAzyme nanocatalysts orchestrate redox-immune coupling for time-gated cancer immunomodulation. (Journal of nanobiotechnology, 2026, PMID 41981590): "The resulting mtDNA leakage activates the cGAS-STING pathway and induces a robust type I interferon response, thereby establishing a transient 4-6 h redox sensitization window."
• May Metabolic reprogramming is critical to microglial activation in Huntington's disease. (JCI insight, 2026, PMID 41926221): "We found that metformin inhibits mitochondrial DNA (mtDNA) release and subsequent neuroinflammation in the cortex and striatum of a mouse model of HD."
• Apr Targeting VDAC1-dependent mtDNA release attenuates fibroblast innate immune activation and vitiligo pathogenesis. (International immunopharmacology, 2026, PMID 41722540): "The released mtDNA activated the cGAS-STING pathway and the NLRP3 inflammasome, driving the expression of IL-1β, IL-6, ICAM-1, and Occludin-a pattern consistent with a senescence-associated secretory phenotype."
• Jun Mitochondrial Haplogroups and Left Ventricular Diastolic Dysfunction in People Living With and Without HIV. (The Journal of infectious diseases, 2026, PMID 41677801): "We investigated whether variations in mitochondrial DNA (mtDNA) and certain dideoxynucleoside analogs (D-drugs) relate to left ventricular diastolic dysfunction (LVDD) in PWH."